(Reuters) – Analysts are cautiously optimistic as second-quarter reporting season rolls out amid this year’s rally in U.S. stocks fueled by optimism over artificial intelligence (AI) and a[...]
Read more
Health
Morgan Stanley hires healthcare services banker Cohen from Truist
By David Carnevali and Svea Herbst-Bayliss NEW YORK (Reuters) – Morgan Stanley has hired veteran investment banker Daniel Cohen from Truist Financial Corp, where he was the head of the firm[...]
Read more
Jurors urged to impose heavy punitive damages in J&J talc trial
By Brendan Pierson (Reuters) – Lawyers for a California man who says he developed a rare cancer from exposure to asbestos in Johnson & Johnson’s talc-based baby powder on Monday urged[...]
Read more
World Bank names CEOs to help bring private funds to climate, development finance
By David Lawder WASHINGTON (Reuters) -The World Bank on Monday named 15 chief executive officers including financiers and asset managers to a group launched by the lender’s president, Ajay Banga[...]
Read more
Schumer asks FDA to investigate Logan Paul’s PRIME energy drink
By Laura Sanicola (Reuters) -U.S. Senate Majority Leader Chuck Schumer on Sunday called on regulators to investigate a popular influencer-created energy drink with nearly twice the caffeine of a Red B[...]
Read more
As earnings loom, investors weigh recession resilience
By David Randall NEW YORK (Reuters) -As second-quarter earnings approach, investors are looking at beaten-down sectors which might gain ground regardless of whether the U.S. economy falls into recessi[...]
Read more
Robots say they won’t steal jobs, rebel against humans
By Emma Farge GENEVA (Reuters) -Robots presented at an AI forum said on Friday they expected to increase in number and help solve global problems, and would not steal humans’ jobs or rebel again[...]
Read more
Bausch + Lomb expands eye-care portfolio with J&J’s Blink
(Reuters) – Bausch + Lomb acquired Johnson & Johnson’s eye and contact lens drops brand Blink for $106.5 million, marking its second deal in two weeks to bolster the contact lens maker[...]
Read more
AbbVie trims full-year profit forecast on higher R&D expenses
(Reuters) -AbbVie Inc cut its full-year profit forecast on Thursday, citing $280 million in milestone and in-process research and development expenses during the second quarter. The company now expect[...]
Read more